Brian Normand and David Nickles are joined by Psymposia Senior Writer Russell Hausfeld to discuss MindMed's CEO, Jamon Rahn's, recent claims that his company "may be creating effectively the Tesla of mental health,” and that the company is now a "$1B+ Unicorn.”

All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.

Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.

We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.

The Psymposia staff reflects on some of the books that kept us company throughout 2020, which we'd like to recommend to our readers for 2021. The list includes works of intersectional analysis, psychedelic history, surveillance capitalism, and more. We hope you appreciate these insights as much as we do.

“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.

Psymposia Advisory Board member Alex Zaitchik drops in to chat about his work and experiences as an investigative journalist with a critical analysis of capitalism. Alex has covered topics ranging from the effects of extractive industry on Indigenous communities, to the existential need for degrowth, and the economics of vaccine development.

The Castalia Foundation — originally founded in part by Timothy Leary — "resurfaced" in 2020 with anti-mask content, praise for Donald Trump, and paranoid discussion around the sexual abuse of children. 

News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.

Before I met Adam I didn’t really know anyone with OCD. It was just an abstract concept to me. Like most people, I had the image of the stereotypical germaphobe who obsessively scrubs their hands in a futile attempt at washing the thousands of bacteria away.